Given previous observation of better responses in MSI CRC patients,151 the preferential enrichment of CD4+ Th1‐like T cells in these patients indicate a positive correlation of these T cells with response to anti‐PD1 treatment. The gene discussed is CD4; the disease is colorectal carcinoma.